ArticleJournal of the Endocrine Society2021
Flash CGM Is Associated With Reduced Diabetes Events and Hospitalizations in Insulin-Treated Type 2 Diabetes.
Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improving Glucose Control and Self-Management in Adults With Type 2 Diabetes From Health Disparate Groups Using Continuous Glucose Monitoring and Education Support
Effect of Monitoring With Freestyle Libre 2 Glucose Sensor on Treatment Satisfaction in Patients With Type 2 Diabetes Mellitus: Exploratory Study in Patients Starting Monitoring
Who cites it
42 citing papers in PubMed, 81 citations in OpenAlex.
- Continuous Glucose Monitoring and Long-Term Glycemic and Kidney Outcomes.JAMA network open · 2026Article
- Real-time continuous glucose monitoring related to reductions in inpatient and emergency department encounters and their associated costs among non-insulin-treated people with type 2 diabetes.Journal of managed care & specialty pharmacy · 2026Article
- Diabetes-related acute care utilization following initiation of automated insulin delivery (AID): A comparison of a disposable tubeless AID system and durable tubed systems.Journal of managed care & specialty pharmacy · 2026Article
- Primary Care-Initiated Continuous Glucose Monitoring in Adults With Insulin-Treated Diabetes.JAMA network open · 2026Article
- Outcomes of Diabetes Management with Continuous Glucose Monitoring Technology.Archives of internal medicine research · 2026Article
- Cost-effectiveness of Freestyle Libre Systems for People with Type 2 Diabetes Mellitus on Basal Insulin Therapy in the Netherlands: An Economic Evaluation from a Societal Perspective Within a Publicly Funded Healthcare System.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Cost-Utility Analysis of FreeStyle Libre Systems in People with Type 2 Diabetes Mellitus on Treatment with Basal Insulin and Poor Glycemic Control in Spain.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Therapeutic Trends in Diabetes Management: A Review on Oral Hypoglycemic Agents (OHAs) Utilization in Tertiary Care.Cardiovascular & hematological disorders drug targets · 2026Review
- Time in Tight Range (TITR) stratified by Time Below Range (TBR) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study.Acta diabetologica · 2025Article
- Economic analyses of freestyle libre systems for people living with diabetes: a systematic literature review.Cost effectiveness and resource allocation : C/E · 2025Review
- Clin-STAR Corner: Practice Changing Advances in Diabetes Care.Journal of the American Geriatrics Society · 2025Review
- Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.Journal of diabetes science and technology · 2025Article
- Narrative Review: Continuous Glucose Monitoring (CGM) in Older Adults with Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Assessing glycaemic impact of FreeStyle libre monitoring in patients with insulin-treated type 2 diabetes: a retrospective real-world analysis.Journal of diabetes and metabolic disorders · 2025Article
- The role of advanced technologies in improving diabetes outcomes.The American journal of managed care · 2025Review
- Determinants of implementation of continuous glucose monitoring for patients with Insulin-Treated type 2 diabetes: a national survey of primary care providers.BMC primary care · 2025Article
- Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.Journal of managed care & specialty pharmacy · 2025Article
- Review
- Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- An AI-based module for interstitial glucose forecasting enabling a "Do-It-Yourself" application for people with type 1 diabetes.Frontiers in digital health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSuboptimal glycemic control among individuals with diabetes is a leading cause of hospitalizations and emergency department utilization. Use of flash continuous glucose monitoring (flash CGM) improves glycemic control in type 1 and type 2 diabetes, which may result in lower risk for acute and chronic complications that require emergency services and/or hospitalizations.
methodsIn this retrospective, real-world study, we analyzed IBM MarketScan Commercial Claims and Medicare Supplemental databases to assess the impact of flash CGM on diabetes-related events and hospitalizations in a cohort of 2463 individuals with type 2 diabetes who were on short- or rapid-acting insulin therapy. Outcomes were changes in acute diabetes-related events (ADE) and all-cause inpatient hospitalizations (ACH), occurring during the first 6 months after acquiring the flash CGM system compared with event rates during the 6 months prior to system acquisition. ICD-10 codes were used to identify ADE for hypoglycemia, hypoglycemic coma, hyperglycemia, diabetic ketoacidosis, and hyperosmolarity.
resultsADE rates decreased from 0.180 to 0.072 events/patient-year (hazard ratio [HR]: 0.39 [0.30, 0.51];
conclusionsAcquisition of the flash CGM system was associated with reductions in ADE and ACH. These findings provide support for the use of flash CGM in type 2 diabetes patients treated with short- or rapid-acting insulin therapy to improve clinical outcomes and potentially reduce costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.